REPORT ARCHIVE

Earnings,
in context.

Quarterly reviews of the companies I own and the ones I’m considering, with dated updates when important evidence changes.

53completed earnings reviews40catalyst check-ins

MOST RECENT FIRST

Reports & check-ins

Ordered by release date. Catalyst updates are marked separately.

CATALYST CHECK-IN · REDEFINE 9 and ObesityWeek clinical update

Released Nov 14, 2026 · Reviewed Nov 16, 2026

Lower-dose efficacy adds flexibility, not a separate valuation premium.

Reported evidence

In the 309-participant REDEFINE 9 trial, CagriSema 1.7/1.7mg and 1.0/1.0mg produced 20.7% and 21.0% estimated weight loss at 68 weeks under the adherence-based efficacy estimand, versus 2.0% placebo. Treatment-regimen estimates were 19.4% and 18.6% versus 4.6%. This strengthens dose-flexibility evidence for the pipeline, not a finding that the lower dose is superior, an approved product or higher recurring earnings. The trial was not powered to compare the two doses.

What to watch

November 15's 25.4% loss is observed on-treatment data among early responders, not the randomized overall REDEFINE 1 population or a new pivotal result. Adverse-event discontinuations in REDEFINE 9 were 2.9%/4.9% versus 4.9% placebo; this does not establish a cross-trial tolerability advantage. Company-reported food-noise associations are retrospective, persistence-selected and not causal proof. The specific company releases/tables were reviewed; the full journal article and broad dynamic news/calendar indexes were not independently completed.

Consider buying

Consider an exploratory entry around $41.63, inside the unchanged $36–42 range and near its upper end; prefer the lower half if net-pricing uncertainty increases. The buy case is the existing cash-generating franchise plus a credible stabilization path, not an assumption that CagriSema wins every competitor comparison. Waiting for a regulatory decision and 2027 pricing clarity could reduce uncertainty but miss a rerating. Persistent earnings erosion below the modeled path invalidates the entry case even inside the band.

Strengthened

Price versus opportunity

Retain fixed DKK 6.523/USD as a historical modeling convention and one ADR per B share. DKK 18/24/28 normalized EPS at 12×/16×/18× gives $33.11/$58.87/$77.27 bear/base/bull, excluding a separate pipeline premium. At $41.63, base is about 41% higher and ordinary bear 20% lower; DKK 14 at 10× is $21.46, about 48% lower, not a floor. Base DKK 24 still needs approximately DKK 315bn sales, 43% operating margin and 78% after-tax conversion on about 4.417bn shares, before financial items. No EPS, probability or multiple uplift follows automatically from these data.

Review price: $41.63 · Nov 13, 2026 close
Current quarter versus prior quarter
MetricPriorCurrentChange
Lower-dose phase 3 efficacyNo randomized lower-dose results in latest Q3 review20.7%/21.0% vs 2.0% placebo, efficacy estimandSupportive; no powered cross-dose superiority
Treatment-regimen estimateAdherence-only headline would be incomplete19.4%/18.6% vs 4.6% placeboIncludes discontinuation/rescue-treatment estimand
Early-response subgroupOverall REDEFINE 1 evidence already known25.4% among early responders, observed on-treatmentPost hoc selection, not new all-participant efficacy
Entry model$36–42; fixed-FX earnings casesSamePipeline credibility improves; recurring cash inputs unchanged

Guidance changes

No new financial guidance or exact regulatory-action date was announced. The company still expects a U.S. CagriSema decision in Q4 2026; it remains investigational and not U.S.-approved in these releases. Broad Q4 timing and conference attendance do not authorize daily checks or an end-of-conference follow-up.

Management language

These are clinical releases, not a new earnings call. The sponsor appropriately distinguishes efficacy from treatment-regimen estimands and calls the early-responder work hypothesis-generating. My inference is improved dose flexibility and commercial optionality, not proof of superior outcomes versus higher-dose CagriSema or competitors. The November 9 6-K is routine repurchase execution, not a new buyback authorization or operating outlook change.

Next checkpoint

Actual regulatory action when announced, product-label and reimbursement economics, and Q4/2027 net-pricing/cash performance. The November 13 close predates weekend data; do not present it as a post-readout reaction or claim the data are priced in.

Milestone timing
MilestonePreviouslyNowMovement
Lower-dose CagriSema dataAwaited trial evidenceNovember 14 randomized REDEFINE 9 data releasedCompleted; no obsolete follow-up retained
U.S. CagriSema actionQ4 2026 expectedSame broad windowNo fixed decision date verified
2027 earnings bridgeNet pricing, cash and launch economics unresolvedNot answered by clinical dataFinancial checkpoint remains essential

What improved

  • Randomized lower-dose evidence broadens the plausible dosing toolkit.
  • The sponsor reports meaningful weight reduction under both estimands, with important design and tolerability qualifications.

No earnings call applies to this update.